146 related articles for article (PubMed ID: 21888260)
1. The future of NSCLC: molecular profiles guiding treatment decisions.
Tsao AS; Papadimitrakopoulou VA
Oncology (Williston Park); 2011 Jun; 25(7):607, 614. PubMed ID: 21888260
[No Abstract] [Full Text] [Related]
2. ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime time.
Socinski MA
Oncology (Williston Park); 2011 Jun; 25(7):601, 604, 607. PubMed ID: 21888259
[No Abstract] [Full Text] [Related]
3. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
Gadgeel SM
Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
[No Abstract] [Full Text] [Related]
4. [Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes].
Besse B
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S93-5. PubMed ID: 26118884
[TBL] [Abstract][Full Text] [Related]
5. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang JC; Neal JW; Niu XM; Wakelee HA
Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
[TBL] [Abstract][Full Text] [Related]
7. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
Rosell R; Karachaliou N; Wolf J; Ou SH
Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349
[No Abstract] [Full Text] [Related]
8. Targeted therapy in lung cancer: survival, quality of life improved for some patients.
Printz C
Cancer; 2014 Sep; 120(17):2625-6. PubMed ID: 25142921
[No Abstract] [Full Text] [Related]
9. Resensitizing Refractory ALK+ NSCLC: A Case Study.
Poh A
Cancer Discov; 2016 Mar; 6(3):220-1. PubMed ID: 26801737
[No Abstract] [Full Text] [Related]
10. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
12. How should "RET positive" NSCLC be treated?
Smit EF
Lung Cancer; 2017 Jun; 108():250-251. PubMed ID: 28189265
[No Abstract] [Full Text] [Related]
13. A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
Biya J; Caramella C; Lindsay CR; Planchard D; Besse B
J Thorac Oncol; 2015 Jun; 10(6):e44-5. PubMed ID: 26001149
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer.
Xie J; Zhang X
J Genet Genomics; 2016 Jan; 43(1):3-10. PubMed ID: 26842989
[TBL] [Abstract][Full Text] [Related]
15. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
Haddad FG; Kourie HR; Kattan J
Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
[No Abstract] [Full Text] [Related]
16. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
Kaczmar J; Mehra R
Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
[TBL] [Abstract][Full Text] [Related]
17. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
Shaw AT
Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
[No Abstract] [Full Text] [Related]
18. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Wijesinghe P; Bollig-Fischer A
Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
[TBL] [Abstract][Full Text] [Related]
19. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
[TBL] [Abstract][Full Text] [Related]
20. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
Costa DB
J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
[No Abstract] [Full Text] [Related]
[Next] [New Search]
